Advertisement

Drugs & Therapy Perspectives

, Volume 34, Issue 8, pp 358–366 | Cite as

Ginkgo biloba extract EGb 761® in the symptomatic treatment of mild-to-moderate dementia: a profile of its use

  • Kate McKeage
  • Katherine A. Lyseng-Williamson
Adis Drug Q&A
  • 66 Downloads

Abstract

EGb 761® (Tanakan®) is a standardized extract of Ginkgo biloba leaves that has demonstrated protective properties against neuronal and vascular damage. Overall, in randomized, placebo-controlled clinical trials and meta-analyses in adults with mild-to-moderate dementia, EGb 761® displayed positive effects, with changes from baseline in outcomes related to cognition, behaviour and global change that are generally better than those shown with placebo. EGb 761® is generally well tolerated, with no safety issues being identified during its many years of widespread use.

Notes

Acknowledgements

The manuscript was reviewed by: M. Mazza, Department of Neurosciences, Institute of Psychiatry, Catholic University of Sacred Heart, Rome, Italy; M.C. Woodward, Aged and Residential Care Services, Austin Health, University of Melbourne, Heidelberg, VIC, Australia; W.S. Zirker, Division of Geriatric Medicine, Crozer-Chester Medical Center, Upland, PA, USA. During the peer review process, Ipsen Pharma, the marketing-authorization holder of EGb 761®, was also offered an opportunity to provide a scientific accuracy review of their data. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Compliance with ethical standards

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

K. McKeage and K.A. Lyseng-Williamson are employees of Adis/Springer, are responsible for the article content and declare no conflicts of interest.

References

  1. 1.
    Sanabria-Castro A, Alvarado-Echeverria I, Monge-Bonilla C. Molecular pathogenesis of Alzheimer’s disease: an update. Ann Neurosci. 2017;24(1):46–54.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Kar S, Slowikowski S, Westaway D, et al. Interactions between β-amyloid and central cholinergic neurons: implications for Alzheimer’s disease. J Psychiatry Neurosci. 2004;29(6):427–41.PubMedPubMedCentralGoogle Scholar
  3. 3.
    O’Brien JT, Holmes C, Jones M, et al. Clinical practice with anti-dementia drugs: a revised (third) consensus statement from the British Association for Psychopharmacology. J Psychopharmacol. 2017;31(2):147–68.CrossRefPubMedGoogle Scholar
  4. 4.
    Wasik A, Antkiewicz-Michaluk L. The mechanism of neuroprotective action of natural compounds. Pharmacol Rep. 2017;69(5):851–60.CrossRefPubMedGoogle Scholar
  5. 5.
    Maclennan KM, Darlington CL, Smith PF. The CNS effects of Ginkgo biloba extracts and ginkgolide B. Prog Neurobiol. 2002;67(3):235–57.CrossRefPubMedGoogle Scholar
  6. 6.
    Kressmann S, Muller WE, Blume HH. Pharmaceutical quality of different Ginkgo biloba brands. J Pharm Pharmacol. 2002;54(5):661–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Kressmann S, Biber A, Wonnemann M, et al. Influence of pharmaceutical quality on the bioavailability of active components from Ginkgo biloba preparations. J Pharm Pharmacol. 2002;54(11):1507–14.CrossRefPubMedGoogle Scholar
  8. 8.
    Tanakan [standardized ginkgo biloba extract (EGb 761)] 40 mg film-coated tablets and 40 mg/ml oral solution: summary of product characteristics (Czech Republic). Boulogne-Billancourt: Ipsen Pharma; 2016.Google Scholar
  9. 9.
    Tanakan [standardized ginkgo biloba extract (EGb 761)] 40 mg film-coated tablets and 40 mg/ml oral solution: summary of product characteristics (Lithuania). Boulogne-Billancourt: Ipsen Pharma; 2015.Google Scholar
  10. 10.
    DeFeudis FV, Drieu K. Ginkgo biloba extract (EGb 761) and CNS functions: basic studies and clinical applications. Curr Drug Targets. 2000;1(1):25–58.CrossRefPubMedGoogle Scholar
  11. 11.
    Ahlemeyer B, Krieglstein J. Neuroprotective effects of Ginkgo biloba extract. Cell Mol Life Sci. 2003;60(9):1779–92.CrossRefPubMedGoogle Scholar
  12. 12.
    De Feudis F. Bilobalide and neuroprotection. Pharmacol Res. 2002;46(6):565–8.CrossRefGoogle Scholar
  13. 13.
    Beck SM, Ruge H, Schindler C, et al. Effects of Ginkgo biloba extract EGb 761® on cognitive control functions, mental activity of the prefrontal cortex and stress reactivity in elderly adults with subjective memory impairment: a randomized double-blind placebo-controlled trial. Hum Psychopharmacol. 2016;31(3):227–42.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Bastianetto S, Quirion R. EGb 761 is a neuroprotective agent against beta-amyloid toxicity. Cell Mol Biol (Noisy-le-Grand). 2002;48(6):693–7.Google Scholar
  15. 15.
    Chen JX, Yan SS. Role of mitochondrial amyloid-beta in Alzheimer’s disease. J Alzheimers Dis. 2010;20(Suppl 2):S569–78.CrossRefPubMedGoogle Scholar
  16. 16.
    Colciaghi F, Borroni B, Zimmermann M, et al. Amyloid precursor protein metabolism is regulated toward alpha-secretase pathway by Ginkgo biloba extracts. Neurobiol Dis. 2004;16(2):454–60.CrossRefPubMedGoogle Scholar
  17. 17.
    Ude C, Schubert-Zsilavecz M, Wurglics M. Ginkgo biloba extracts: a review of the pharmacokinetics of the active ingredients. Clin Pharmacokinet. 2013;52(9):727–49.CrossRefPubMedGoogle Scholar
  18. 18.
    Bridi R, Crossetti FP, Steffen VM, et al. The antioxidant activity of standardized extract of Ginkgo biloba (EGb 761) in rats. Phytother Res. 2001;15(5):449–51.CrossRefPubMedGoogle Scholar
  19. 19.
    Wei T, Ni Y, Hou J, et al. Hydrogen peroxide-induced oxidative damage and apoptosis in cerebellar granule cells: protection by Ginkgo biloba extract. Pharmacol Res. 2000;41(4):427–33.CrossRefPubMedGoogle Scholar
  20. 20.
    Sastre J, Millan A, Garcia de la Asuncion J, et al. A Ginkgo biloba extract (EGb 761) prevents mitochondrial aging by protecting against oxidative stress. Free Radic Biol Med. 1998;24(2):298–304.CrossRefPubMedGoogle Scholar
  21. 21.
    Rocher MN, Carre D, Spinnewyn B, et al. Long-term treatment with standardized Ginkgo biloba extract (EGb 761) attenuates cognitive deficits and hippocampal neuron loss in a gerbil model of vascular dementia. Fitoterapia. 2011;82(7):1075–80.CrossRefPubMedGoogle Scholar
  22. 22.
    Wang Y, Wang L, Wu J, et al. The in vivo synaptic plasticity mechanism of EGb 761-induced enhancement of spatial learning and memory in aged rats. Br J Pharmacol. 2006;148(2):147–53.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Williams B, Watanabe CMH, Schultz PG, et al. Age-related effects of Ginkgo biloba extract on synaptic plasticity and excitability. Neurobiol Aging. 2004;25(7):955–62.CrossRefPubMedGoogle Scholar
  24. 24.
    Tchantchou F, Xu Y, Wu Y, et al. EGb 761 enhances adult hippocampal neurogenesis and phosphorylation of CREB in transgenic mouse model of Alzheimer’s disease. FASEB J. 2007;21(10):2400–8.CrossRefPubMedGoogle Scholar
  25. 25.
    Chandrasekaran K, Mehrabian Z, Spinnewyn B, et al. Neuroprotective effects of bilobalide, a component of Ginkgo biloba extract (EGb 761) in global brain ischemia and in excitotoxicity-induced neuronal death. Pharmacopsychiatry. 2003;36(Suppl 1):S89–94.PubMedGoogle Scholar
  26. 26.
    Mdzinarishvili A, Sumbria R, Lang D, et al. Ginkgo extract EGb761 confers neuroprotection by reduction of glutamate release in ischemic brain. J Pharm Pharm Sci. 2012;15(1):94–102.CrossRefPubMedGoogle Scholar
  27. 27.
    Soulie C, Nicole A, Christen Y, et al. The Ginkgo biloba extract EGb 761 increases viability of hnt human neurons in culture and affects the expression of genes implicated in the stress response. Cell Mol Biol. 2002;48(6):641–6.PubMedGoogle Scholar
  28. 28.
    Mohamed NE, Abd El-Moneim AE. Ginkgo biloba extract alleviates oxidative stress and some neurotransmitters changes induced by aluminum chloride in rats. Nutrition. 2017;35:93–9.CrossRefPubMedGoogle Scholar
  29. 29.
    Shi C, Zhao L, Zhu B, et al. Protective effects of Ginkgo biloba extract (EGb761) and its constituents quercetin and ginkgolide B against beta-amyloid peptide-induced toxicity in SH-SY5Y cells. Chem Biol Interact. 2009;181(1):115–23.CrossRefPubMedGoogle Scholar
  30. 30.
    Smith JV, Luo Y. Elevation of oxidative free radicals in Alzheimer’s disease models can be attenuated by Ginkgo biloba extract EGb 761. J Alzheimers Dis. 2003;5(4):287–300.CrossRefPubMedGoogle Scholar
  31. 31.
    Wang N, Chen X, Geng D, et al. Ginkgo biloba leaf extract improves the cognitive abilities of rats with d-galactose induced dementia. J Biomed Res. 2013;27(1):29–36.PubMedGoogle Scholar
  32. 32.
    Yao Z, Drieu K, Papadopoulos V. The Ginkgo biloba extract EGb 761 rescues the PC12 neuronal cells from beta-amyloid-induced cell death by inhibiting the formation of beta-amyloid-derived diffusible neurotoxic ligands. Brain Res. 2001;889(1–2):181–90.CrossRefPubMedGoogle Scholar
  33. 33.
    Luo Y, Smith JV, Paramasivam V, et al. Inhibition of amyloid-beta aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761. Proc Natl Acad Sci USA. 2002;99(19):12197–202.CrossRefPubMedGoogle Scholar
  34. 34.
    Stackman RW, Eckenstein F, Frei B, et al. Prevention of age-related spatial memory deficits in a transgenic mouse model of Alzheimer’s disease by chronic Ginkgo biloba treatment. Exp Neurol. 2003;184(1):510–20.CrossRefPubMedGoogle Scholar
  35. 35.
    Yao Z, Han Z, Drieu K, et al. Ginkgo biloba extract (Egb 761) inhibits β-amyloid production by lowering free cholesterol levels. J Nutr Biochem. 2004;15(12):749–56.CrossRefPubMedGoogle Scholar
  36. 36.
    Longpré F, Garneau P, Christen Y, et al. Protection by EGb 761 against β-amyloid-induced neurotoxicity: involvement of NF-κB, SIRT1, and MAPKs pathways and inhibition of amyloid fibril formation. Free Radic Biol Med. 2006;41(12):1781–94.CrossRefPubMedGoogle Scholar
  37. 37.
    Rhein V, Giese M, Baysang G, et al. Ginkgo biloba extract ameliorates oxidative phosphorylation performance and rescues Aβ-induced failure. PLoS One. 2010;5(8):e12359.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Kwon KJ, Lee EJ, Cho KS, et al. Ginkgo biloba extract (Egb761) attenuates zinc-induced tau phosphorylation at Ser262 by regulating GSK3beta activity in rat primary cortical neurons. Food Funct. 2015;6(6):2058–67.CrossRefPubMedGoogle Scholar
  39. 39.
    Paganelli RA, Benetoli A, Milani H. Sustained neuroprotection and facilitation of behavioral recovery by the Ginkgo biloba extract, EGb 761, after transient forebrain ischemia in rats. Behav Brain Res. 2006;174(1):70–7.CrossRefPubMedGoogle Scholar
  40. 40.
    Zhao J, Jin KK, Wu L, et al. Effects of extract of Ginkgo biloba on learning and memory ability and NGF and NT-3 expression in diabetic rats. Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2012;28(5):467–71.PubMedGoogle Scholar
  41. 41.
    Winter JC. The effects of an extract of Ginkgo biloba, EGb 761, on cognitive behavior and longevity in the rat. Physiol Behav. 1998;63(3):425–33.CrossRefPubMedGoogle Scholar
  42. 42.
    Shif O, Gillette K, Damkaoutis CM, et al. Effects of Ginkgo biloba administered after spatial learning on water maze and radial arm maze performance in young adult rats. Pharmacol Biochem Behav. 2006;84(1):17–25.CrossRefPubMedGoogle Scholar
  43. 43.
    Chen LE, Wu F, Zhao A, et al. Protection efficacy of the extract of Ginkgo biloba against the learning and memory damage of rats under repeated high sustained +Gz exposure. Evid Based Complement Altern Med. 2016;2016:6320586.Google Scholar
  44. 44.
    Tighilet B, Lacour M. Pharmacological activity of the Ginkgo biloba extract (EGb 761) on equilibrium function recovery in the unilateral vestibular neurectomized cat. J Vestib Res. 1995;5(3):187–200.CrossRefPubMedGoogle Scholar
  45. 45.
    Silberstein RB, Pipingas A, Song J, et al. Examining brain-cognition effects of Ginkgo biloba extract: brain activation in the left temporal and left prefrontal cortex in an object working memory task. Evid Based Complement Altern Med. 2011;2011:164139.CrossRefGoogle Scholar
  46. 46.
    Schneider LS, DeKosky ST, Farlow MR, et al. A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer’s type. Curr Alzheimer Res. 2005;2(5):541–51.CrossRefPubMedGoogle Scholar
  47. 47.
    Kanowski S, Hoerr R. Ginkgo biloba extract EGb 761 in dementia: intent-to-treat analyses of a 24-week, multi-center, double-blind, placebo-controlled, randomized trial. Pharmacopsychiatry. 2003;36(6):297–303.CrossRefPubMedGoogle Scholar
  48. 48.
    Le Bars PL, Katz MM, Berman N, et al. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. JAMA. 1997;278(16):1327–32.CrossRefPubMedGoogle Scholar
  49. 49.
    Le Bars PL, Kieser M, Itil KZ. A 26-week analysis of a double-blind, placebo-controlled trial of the Ginkgo biloba extract EGb 761 in dementia. Dement Geriatr Cogn Disord. 2000;11:230–7.CrossRefPubMedGoogle Scholar
  50. 50.
    McCarney R, Fisher P, Iliffe S, et al. Ginkgo biloba for mild to moderate dementia in a community setting: a pragmatic randomised, parallel-group, double-blind, placebo-controlled trial. Int J Geriatr Psychiatry. 2008;23(12):1222–30.CrossRefPubMedGoogle Scholar
  51. 51.
    van Dongen M, van Rossum E, Kessels A, et al. Ginkgo for elderly people with dementia and age-associated memory impairment: a randomized clinical trial. J Clin Epidemiol. 2003;56(4):367–76.CrossRefPubMedGoogle Scholar
  52. 52.
    van Dongen MCJM, van Rossum E, Kessels AGH, et al. The efficacy of ginkgo for elderly people with dementia and age-associated memory impairment: new results of a randomized clinical trial. J Am Geriatr Soc. 2000;48(10):1183–94.CrossRefPubMedGoogle Scholar
  53. 53.
    Herrschaft H, Nacu A, Likhachev S, et al. Ginkgo biloba extract EGb 761® in dementia with neuropsychiatric features: a randomised, placebo-controlled trial to confirm the efficacy and safety of a daily dose of 240 mg. J Psychiatr Res. 2012;46(6):716–23.CrossRefPubMedGoogle Scholar
  54. 54.
    Ihl R, Bachinskaya N, Korczyn AD, et al. Efficacy and safety of a once-daily formulation of Ginkgo biloba extract EGb 761 in dementia with neuropsychiatric features: a randomized controlled trial. Int J Geriatr Psychiatry. 2011;26(11):1186–94.PubMedGoogle Scholar
  55. 55.
    Ihl R, Tribanek M, Bachinskaya N. Efficacy and tolerability of a once daily formulation of Ginkgo biloba extract EGb 761® in Alzheimer’s disease and vascular dementia: results from a randomised controlled trial. Pharmacopsychiatry. 2012;45(2):41–6.CrossRefPubMedGoogle Scholar
  56. 56.
    Napryeyenko O, Borzenko I. Ginkgo biloba special extract in dementia with neuropsychiatric features: a randomised, placebo-controlled, double-blind clinical trial. Arzneimittelforschung. 2007;57(1):4–11.PubMedGoogle Scholar
  57. 57.
    Napryeyenko O, Sonnik G, Tartakovsky I. Efficacy and tolerability of Ginkgo biloba extract EGb 761 by type of dementia: analyses of a randomised controlled trial. J Neurol Sci. 2009;283(1–2):224–9.CrossRefPubMedGoogle Scholar
  58. 58.
    Nikolova G, Yancheva S, Raychev I, et al. Ginkgo biloba extract in dementia: a 22-week randomised, placebo-controlled, double-blind trial [in Bulgarian]. Bulg Neurol. 2013;14(3):139–43.Google Scholar
  59. 59.
    Brondino N, De Silverstri A, Re S, et al. A systematic review and meta-analysis of Ginkgo biloba in neuropsychiatric disorders: from ancient tradition to modern-day medicine. Evid Based Complement Altern Med. 2013;2013:915691.  https://doi.org/10.1155/2013/915691.CrossRefGoogle Scholar
  60. 60.
    Gauthier S, Schlaefke S. Efficacy and tolerability of Ginkgo biloba extract EGb 761® in dementia: a systematic review and meta-analysis of randomized placebo-controlled trials. Clin Interv Aging. 2014;9:2065–77.CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Hashiguchi M, Ohta Y, Shimizu M, et al. Meta-analysis of the efficacy and safety of Ginkgo biloba extract for the treatment of dementia. J Pharm Health Care Sci. 2015;1:14.  https://doi.org/10.1186/s40780-015-0014-7.CrossRefPubMedPubMedCentralGoogle Scholar
  62. 62.
    Jiang L, Su L, Cui H, et al. Ginkgo biloba extract for dementia: a systematic review. Shanghai Arch Psychiatry. 2013;25(1):10–2.PubMedPubMedCentralGoogle Scholar
  63. 63.
    Tan MS, Yu JT, Tan CC, et al. Efficacy and adverse effects of Ginkgo biloba for cognitive impairment and dementia: a systematic review and meta-analysis. J Alzheimers Dis. 2015;43(2):589–603.CrossRefPubMedGoogle Scholar
  64. 64.
    Maurer K, Ihl R, Dierks T, et al. Clinical efficacy of Ginkgo biloba special extract EGb 761 in dementia of the Alzheimer type. J Psychiatr Res. 1997;31(6):645–55.CrossRefPubMedGoogle Scholar
  65. 65.
    Mazza M, Capuano A, Bria P, et al. Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer’s dementia in a randomized placebo-controlled double-blind study. Eur J Neurol. 2006;13(9):981–5.CrossRefPubMedGoogle Scholar
  66. 66.
    Gaus W, et al. An example for an underpowered study: a comment on Ginkgo biloba for mild to moderate dementia in a community setting by McCarney et al. [letter]. Int J Geriatr Psychiatry. 2009;24(2):216–7.CrossRefPubMedGoogle Scholar
  67. 67.
    Yancheva S, Ihl R, Nikolova G, et al. Ginkgo biloba extract EGb 761®, donepezil or both combined in the treatment of Alzheimer’s disease with neuropsychiatric features: a randomised, double-blind, exploratory trial. Aging Ment Health. 2009;13(2):183–90.CrossRefPubMedGoogle Scholar
  68. 68.
    Canevelli M, Adali N, Kelaiditi E, et al. Effects of Gingko biloba supplementation in Alzheimer’s disease patients receiving cholinesterase inhibitors: data from the ICTUS study. Phytomedicine. 2014;21(6):888–92.CrossRefPubMedGoogle Scholar
  69. 69.
    Kanowski S, Herrmann WM, Stephan K, et al. Proof of efficacy of the Ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia. Pharmacopsychiatry. 1996;29(2):47–56.CrossRefPubMedGoogle Scholar
  70. 70.
    Heinonen T, Gaus W. Cross matching observations on toxicological and clinical data for the assessment of tolerability and safety of Ginkgo biloba leaf extract. Toxicology. 2015;327:95–115.CrossRefPubMedGoogle Scholar
  71. 71.
    European Union herbal monograph on Ginkgo biloba L., folium. London; European Medicines Agency; 2015.Google Scholar
  72. 72.
    Dit Sollier CB, Caplain H, Drouet L. No alteration in platelet function or coagulation induced by EGb761 in a controlled study. Clin Lab Haematol. 2003;25(4):251–3.CrossRefGoogle Scholar
  73. 73.
    Gardner C, Zehnder J, Rigby A, et al. Effects of Ginkgo biloba (EGb 761) and aspirin on platelet aggregation and platelet function analysis among older adults at risk of cardiovascular disease: a randomized clinical trial. Blood Coagul Fibrinolysis. 2007;18(8):787–93.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations